Thalys(SH:603716) Zheng Quan Zhi Xing·2025-06-20 12:07Fundraising Overview - The company, Sealy Medical Technology Group Co., Ltd., raised a total of approximately RMB 625.96 million through a private placement of 26,853,709 shares at a price of RMB 23.31 per share, as approved by the China Securities Regulatory Commission in 2018 [1][2] - The net amount raised after deducting issuance costs was confirmed by a verification report from a certified public accounting firm [1] Fund Management and Regulatory Compliance - The company has established a dedicated bank account for the management of the raised funds and signed a tripartite supervision agreement with the bank and the sponsor, ensuring compliance with relevant regulations [2][3] - A new special account was set up at Jiangsu Sushang Bank to manage the funds for the 2018 non-public offering project aimed at expanding the scale of medical testing services, with no changes to the intended use of the funds [2][3] Tripartite Supervision Agreement - The tripartite agreement involves Sealy Medical as Party A, Jiangsu Sushang Bank as Party B, and the sponsor, Xinda Securities, as Party C, ensuring that the funds are used solely for the specified project [3][4] - The agreement stipulates that the funds must not be used for any other purposes and outlines the responsibilities of each party in monitoring and managing the funds [4][5] Fund Usage and Reporting - The company is required to notify the sponsor within five working days of any fund disbursement and provide a detailed expenditure list [5] - The agreement remains effective until all funds are fully utilized and the account is legally closed [5]